Silvia Mccoll Wealth Management LLC Takes $211,000 Position in Cencora, Inc. (NYSE:COR)

Silvia Mccoll Wealth Management LLC bought a new stake in shares of Cencora, Inc. (NYSE:COR) in the 1st quarter, Holdings Channel reports. The firm bought 888 shares of the company’s stock, valued at approximately $211,000.

A number of other hedge funds also recently added to or reduced their stakes in the company. Rise Advisors LLC purchased a new position in Cencora in the 1st quarter worth approximately $25,000. CVA Family Office LLC purchased a new position in Cencora in the 1st quarter worth approximately $34,000. Bruce G. Allen Investments LLC purchased a new position in Cencora in the 1st quarter worth approximately $43,000. Kathmere Capital Management LLC raised its holdings in Cencora by 15.2% in the 1st quarter. Kathmere Capital Management LLC now owns 1,498 shares of the company’s stock worth $364,000 after acquiring an additional 198 shares during the last quarter. Finally, Iron Horse Wealth Management LLC purchased a new position in Cencora in the 1st quarter worth approximately $64,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird lifted their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Citigroup lifted their target price on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Finally, SVB Leerink reaffirmed an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $235.30.

Insiders Place Their Bets

In related news, Director Dermot Mark Durcan purchased 500 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were acquired at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now directly owns 21,876 shares in the company, valued at $4,781,656.08. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the sale, the insider now directly owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dermot Mark Durcan bought 500 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were acquired at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the completion of the transaction, the director now directly owns 21,876 shares in the company, valued at approximately $4,781,656.08. The disclosure for this purchase can be found here. Insiders have sold a total of 1,956,675 shares of company stock worth $422,352,056 in the last 90 days. 15.80% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Shares of COR stock traded down $1.72 during mid-day trading on Monday, reaching $223.58. 1,723,139 shares of the company’s stock traded hands, compared to its average volume of 1,409,780. Cencora, Inc. has a 12 month low of $171.65 and a 12 month high of $246.75. The firm has a 50 day moving average price of $229.12 and a two-hundred day moving average price of $228.16. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The firm has a market capitalization of $44.59 billion, a PE ratio of 24.65, a price-to-earnings-growth ratio of 1.57 and a beta of 0.45.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. During the same quarter in the previous year, the company earned $3.50 EPS. Cencora’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, research analysts forecast that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a yield of 0.91%. The ex-dividend date was Thursday, May 9th. Cencora’s payout ratio is currently 22.32%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.